Glucagon-like peptide-1

Reverse-phase silica media for GLP‑1 and other peptides; available in C8 and C18 chemistries for high-resolution separations and integration with AmberChrom polymeric resins from development to manufacturing.

Approvals include Rasonque for metastatic pancreatic cancer, Foundayo oral GLP‑1 for weight and type 2 diabetes, Yuviwel for achondroplasia, two biosimilars and temozolomide for gliomas.

Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.

MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.

Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.

Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.

First GIP+GLP‑1 agonist authorised to lower major adverse cardiovascular events in high‑risk adults with type 2 diabetes; SURPASS‑CVOT enrolled >13,000 with ~4‑year median follow‑up.

First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.

Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.